Evidence map›Paper›PMID 36928373›Full record

ReviewCancer immunology, immunotherapy : CII2023

Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.

Aleksandra Semeniuk-Wojtaś, Karolina Poddębniak-Strama, Magdalena Modzelewska, Maksymilian Baryła, Ewelina Dziąg-Dudek, Tomasz Syryło, Barbara Górnicka, Anna Jakieła, Rafał Stec

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aleksandra Semeniuk-WojtaśOncology Department, Medical University of Warsaw, Warsaw, Poland. asemeniukwojtas@gmail.com.
Karolina Poddębniak-StramaOncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland.
Magdalena ModzelewskaPathomorphology Department, Medical University of Warsaw, Warsaw, Poland.
Maksymilian BaryłaOncology Department, Medical University of Warsaw, Warsaw, Poland.
Ewelina Dziąg-DudekOncology Department, Medical University of Warsaw, Warsaw, Poland.
Tomasz SyryłoDepartment of General, Active and Oncological Urology, Military Institute of Medicine, Warsaw, Poland.
Barbara GórnickaPathomorphology Department, Medical University of Warsaw, Warsaw, Poland.
Anna JakiełaOncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland.
Rafał StecOncology Department, Medical University of Warsaw, Warsaw, Poland.
Medical University of Warsaw · PL1 Military Clinical Hospital with Outpatient Clinic · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) can be divided into two subgroups depending on invasion of the muscular layer: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Its aggressiveness is associated, inter alia, with genetic aberrations like losses of 1p, 6q, 9p, 9q and 13q; gain of 5p; or alterations in the p53 and p16 pathways. Moreover, there are reported metabolic disturbances connected with poor diagnosis-for example, enhanced aerobic glycolysis, gluconeogenesis or haem catabolism.Currently, the primary way of treatment method is transurethral resection of the bladder tumour (TURBT) with adjuvant Bacillus Calmette-Guérin (BCG) therapy for NMIBC or radical cystectomy for MIBC combined with chemotherapy or immunotherapy. However, intravesical BCG immunotherapy and immune checkpoint inhibitors are not efficient in every case, so appropriate biomarkers are needed in order to select the proper treatment options. It seems that the success of immunotherapy depends mainly on the tumour microenvironment (TME), which reflects the molecular disturbances in the tumour. TME consists of specific conditions like hypoxia or local acidosis and different populations of immune cells including tumour-infiltrating lymphocytes, natural killer cells, neutrophils and B lymphocytes, which are responsible for shaping the response against tumour neoantigens and crucial pathways like the PD-L1/PD-1 axis.In this review, we summarise holistically the impact of the immune system, genetic alterations and metabolic changes that are key factors in immunotherapy success. These findings should enable better understanding of the TME complexity in case of NMIBC and causes of failures of current therapies.

Indexed as

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineHumansImmunotherapyNeoplasm InvasivenessTumor MicroenvironmentAdjuvants, ImmunologicBCG VaccineBladder cancerCancer phenotypeImmunotheraphyMicroenvironmentNMIBC

Identifiers

PMID36928373
PMCPMC10264486
OpenAlexW4327675589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.